A Prospective, Randomized Comparison of Promus Everolimus-Eluting and TAXUS Liberte Paclitaxel-Eluting Stent Systems in Patients with Coronary Artery Disease Eligible for Percutaneous Coronary Intervention: The PROMISE Study.
10.3346/jkms.2013.28.11.1609
- Author:
Ung KIM
1
;
Chan Hee LEE
;
Jung Hwan JO
;
Hyun Wook LEE
;
Yoon Jung CHOI
;
Jang Won SON
;
Sang Hee LEE
;
Jong Seon PARK
;
Dong Gu SHIN
;
Young Jo KIM
;
Myung Ho JEONG
;
Myung Chan CHO
;
Jang Ho BAE
;
Jae Hwan LEE
;
Tae Soo KANG
;
Kyung Tae JUNG
;
Kyung Ho JUNG
;
Seung Wook LEE
;
Jang Hyun CHO
;
Won KIM
;
Seung Ho HUR
;
Ki Sik KIM
;
Heon Sik PARK
;
Moo Hyun KIM
;
Jin Yong HWANG
;
Doo Il KIM
;
Tae Ik KIM
Author Information
1. Division of Cardiology, Yeungnam University Medical Center, Daegu, Korea. yjkim@med.yu.ac.kr
- Publication Type:Original Article ; Comparative Study ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
- Keywords:
Everolimus-Eluting Stent;
Paclitaxel-Eluting Stent
- MeSH:
Antineoplastic Agents, Phytogenic/administration & dosage/therapeutic use;
Coronary Artery Disease/*drug therapy/mortality;
Coronary Restenosis/prevention & control;
*Drug-Eluting Stents;
Female;
Humans;
Immunosuppressive Agents/administration & dosage/therapeutic use;
Male;
Middle Aged;
Paclitaxel/administration & dosage/*therapeutic use;
Percutaneous Coronary Intervention/*methods;
Prospective Studies;
Sirolimus/administration & dosage/*analogs & derivatives/therapeutic use;
Thrombosis;
Treatment Outcome
- From:Journal of Korean Medical Science
2013;28(11):1609-1614
- CountryRepublic of Korea
- Language:English
-
Abstract:
We aimed comparing two-year clinical outcomes of the Everolimus-Eluting Promus and Paclitaxel-Eluting TAXUS Liberte stents used in routine clinical practice. Patients with objective evidence of ischemia and coronary artery disease eligible for PCI were prospectively randomized to everolimus-eluting stent (EES) or paclitaxel-eluting stent (PES) groups. The primary end-point was ischemia-driven target vessel revascularization (TVR) at 2 yr after intervention, and the secondary end-point was a major adverse cardiac event (MACE), such as death, myocardial infarction (MI), target lesion revascularization (TLR), TVR or stent thrombosis. A total of 850 patients with 1,039 lesions was randomized to the EES (n=425) and PES (n=425) groups. Ischemic-driven TVR at 2 yr was 3.8% in the PES and 1.2% in the EES group (P for non-inferiority=0.021). MACE rates were significantly different; 5.6% in PES and 2.5% in EES (P = 0.027). Rates of MI (0.8% in PES vs 0.2% in EES, P = 0.308), all deaths (1.5% in PES vs 1.2% in EES, P = 0.739) and stent thrombosis (0.3% in PES vs 0.7% in EES, P = 0.325) were similar. The clinical outcomes of EES are superior to PES, mainly due to a reduction in the rate of ischemia-driven TVR.
